Evaluation of the performance of a lateral flow device for quantitative detection of anti-SARS-CoV-2 IgG

J.S. Moore, L.J. Robertson, R. Price, G. Curry, J. Farnan, A. Black, M.A. Nesbit, J.A. McLaughlin, T. Moore

Research output: Contribution to journalArticlepeer-review

34 Downloads (Pure)


Introduction: The AbC-19™ lateral flow immunoassay (LFIA) performance was evaluated on plasma samples from a SARS-CoV-2 vaccination cohort, WHO international standards for anti-SARS-CoV-2 IgG (human), individuals ≥2 weeks from infection of RT-PCR confirmed SARS-CoV-2 genetic variants, as well as microorganism serology. Methods: Pre-vaccination to three weeks post-booster samples were collected from a cohort of 111 patients (including clinically extremely vulnerable patients) from Northern Ireland. All patients received Oxford-AstraZeneca COVID-19 vaccination for the first and second dose, and Pfizer-BioNTech for the third (first booster). WHO international standards, 15 samples from 2 variants of concern (Delta and Omicron) and cross-reactivity with plasma samples from other microorganism infections were also assessed on AbC-19™. Results: All 80 (100%) participants sampled post-booster had high positive IgG responses, compared to 38/95 (40%) participants at 6 months post-first vaccination. WHO standard results correlated with information from corresponding biological data sheets, and antibodies to all genetic variants were detected by LFIA. No cross-reactivity was found with exception of one (of five) Dengue virus samples. Conclusion: These findings suggest BNT162b2 booster vaccination enhanced humoral immunity to SARS-CoV-2 from pre-booster levels, and that this antibody response was detectable by the LFIA. In combination with cross-reactivity, standards and genetic variant results would suggest LFIA may be a cost-effective measure to assess SARS-CoV-2 antibody status.
Original languageEnglish
Pages (from-to)130-135
Number of pages6
JournalClinical Immunology Communications
Early online date14 Sept 2022
Publication statusPublished (in print/issue) - 31 Dec 2022

Bibliographical note

Funding information:
The study was funded by Abingdon Health, United Kingdom who also provided the AbC-19™ testing devices. Abingdon Health had no other involvement in the study.


  • SARS-CoV-2
  • lateral flow immunoassay
  • Antibody
  • Vaccine
  • Variant


Dive into the research topics of 'Evaluation of the performance of a lateral flow device for quantitative detection of anti-SARS-CoV-2 IgG'. Together they form a unique fingerprint.

Cite this